openPR Logo
Press release

IAMA - HONORARY LIFE MEMBERSHIP AWARD" 2018 is awarded to CHRISTIAN MAY

06-29-2018 10:17 AM CET | Arts & Culture

Press release from: MELOS KONZERTE

Christian May@MKW Wien.jpg

Christian May@MKW Wien.jpg

The "IAMA - HONORARY LIFE MEMBERSHIP AWARD" for 2018 is awarded to CHRISTIAN MAY

The international music and artist manager CHRISTIAN MAY receives this years "IAMA - HONORARY LIFE MEMBERSHIP AWARD"
The prestigious award, which has been given to twelve music managers worldwide only since the foundation of the "International Artist Managers' Association - IAMA", was presented to Christian May in London by IAMA chair Aino Turtiainen.
The award counts among the most coveted accolades in the field of music management and is given in recognition of outstanding services to the profession by a manager.

"The HONORARY LIFE MEMBERSHIP AWARD is only awarded from time to time and is IAMA's highest honour in recognition of services to the profession." (IAMA - 2018)

CHRISTIAN MAY, born in Munich, studied composition and conducting as well as International Law in Munich, Vienna and London.
Following his studies he worked as musical assistant and later as tour manager for various opera and orchestra tours. In 1991 he founded the concert agency MELOS KONZERTE in Vienna. The agency's focus is the general management of conductors and soloists, the organization of orchestra tours and recording projects. Since 2010 the agency has a subdivision dealing exclusively with film music recordings, working mainly for clients in France, Italy and the UK.

In 2013 he set up a joined venture HSO PRODUCTIONS with partners in France and Hungary for the production of orchestra recordings, which counts labels like UNIVERSAL, DEUTSCHE GRAMMOPHON, NAXOS and CLAVES among its clients.
Christian May is artistic advisor for a number of festivals and orchestras in Europe and South America. He acted as jury member for competitions in Switzerland, Italy, Mexico and Portugal, has been for various years on the jury of the MIDEM CLASSICAL AWARD in Cannes and was lecturer for Arts Management at the Musikhochschule Stuttgart.
He has been on the advisory board of CLASSICAL NEXT, is a member of the "Federation for Asian Cultural Promotion - FACP" as well as a board member of the „Classical Music Artists Directory“.

The "INTERNATIONAL ARTIST MANAGERS' ASSOCIATION " (IAMA) is the only worldwide association for classical music artist managers. The Association was founded as the British Association of Concert Agents in 1954 until January 1996 when, due to its international membership list, it changed its status to an international association.
IAMA has presently more then 300 members worldwide (artist management companies, presenters, orchestras, opera companies, festivals and venues) and strives to raise professional standards in the business of music. It acts as a lobbying body within member territories as well as facilitating information exchange within its network of members.
Since 1991 there has been an annual international conference now recognised as one of the premiere forums in the classical music world.

Eleonore Schmidt (PR & Media)

MELOS KONZERTE
Salesianergasse 12/11
A-1030 Wien

Tel: +43-1-7149196
mail: es@melos.at

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IAMA - HONORARY LIFE MEMBERSHIP AWARD" 2018 is awarded to CHRISTIAN MAY here

News-ID: 1102744 • Views:

More Releases for IAMA

Epilepsy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals …
DelveInsight's, "Epilepsy Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space. Explore our latest breakthroughs in Epilepsy Research. Learn more
Epilepsy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatmen …
DelveInsight's, "Epilepsy - Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Epilepsy Pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy
Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working …
DelveInsight's, "Epilepsy Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space. Explore our latest breakthroughs in Epilepsy Research. Learn more
Epilepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessmen …
Epilepsy Pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analyzes DelveInsight. Epilepsy Overview: Epilepsy is a prevalent and serious neurological condition affecting over 50 million people globally. It is characterized by a chronic predisposition to epileptic seizures, along with associated cognitive, psychological, and social challenges. The condition exhibits a bimodal incidence pattern, with the highest risk occurring in infants and the elderly. An epileptic seizure refers to
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Epilepsy Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emergi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Epilepsy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market. The Epilepsy Pipeline report embraces in-depth